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Introduction

Animals and treatments
Cytostatic combinations that include the alkylating agent, buFemale BALB/c mice, 8-10 weeks old were bred and held in sulphan (BU), have been widely used instead of supralethal an SPF animal facility at the National Institute of Oncology total body irradiation (TBI) for myeloablation before bone (Budapest, Hungary). They had ad libitum access to automarrow transplantation (BMT). Depending on the disease claved diet and acidified water. Before the experiment mice parameter studied, these preparatory regimens have relative were weighed and randomized in different treatment groups, advantages and disadvantages, however, they appear to have each consisting of five to six animals, except when indicated comparable risk for acute GVHD and most other post-BMT otherwise. The drug suspensions were thoroughly mixed complications. [1] [2] [3] [4] [5] [6] [7] [8] This seems, however, not to be the case before i.p. injection in a volume of 0.5 ml. with a novel, radiation-free, non-supralethal myelosuppressive protocol, in which BU is replaced by another alkylating agent, mitobronitol (dibromomannitol, DBM). Studies by Kelemen et al 3 demonstrated that preconditioning of accelerated Measurement of lymphoid organ toxicity CGL patients with DBM/cytarabine (Ara-C)/Cy combination before allogeneic BMT resulted in a significant reduction of Mice selected randomly for the assessment of organ toxicity post-BMT complications relative to the corresponding indices were sacrificed at the indicated time by cervical dislocation. reported by major BMT centers for other protocols, including
The spleen and thymus were removed, blotted on paper, TBI, TBI/Cy and BU/Cy. The difference was most remarkable weighed in an analytical balance and processed further as for acute GVHD, but the frequency of other complications, eg follows. veno-occlusive liver disease, diffuse interstitial pneumonitis, severe mucositis, fungal infections, sepsis, were also significantly lowered. 3 The most recent update provided further eviAnalysis of T cell markers in the spleen dence for an impressive prophylactic effect of the DBM/Ara-C/Cy combination for many complications of BMT (Kelemen Details of the flow cytometric analysis were described preet al, manuscript in preparation).
viously. 13 In brief, the spleen was homogenized in Medium It is known that the rise of GVHD along with the various 199, and 5 × 10 5 cells in 50 l volume (in the wells of 96-bacterial and/or fungal infections are due to the myelowell U-bottom plates) were stained with 1:100 diluted rat ablation-induced immunosuppression that endures over a monoclonal anti-Thy-1.2 (30-H12) antibodies. Following long time after BMT. [9] [10] [11] [12] Thus, one possible explanation for incubation at 4°C for 20 min, cells were washed twice and the above clinical observations is that the immune reconstiincubated with FITC-conjugated mouse anti-rat IgG (Becton Dickinson, Mountain View, CA, USA 1:40 dilution) for 20 min at room temperature. Stained cells were washed once and Mitogen-induced lymphocyte proliferation Splenic lymphocytes were separated by Ficoll-Uromiro gradient centrifugation, and 2 × 10 5 cells (in 200 l complete RPMI 1640 medium in the wells of 96-well plates) were stimulated either with 10 g/ml E. coli 055:B5 lipopolysaccharide (LPS) (Sigma Chemicals, St Louis, MO, USA), or with 5 g/ml concanavalin A (ConA) (Sigma) for 2 days in a CO 2 incubator. After pulsing with 3 H-thymidine, lymphocytes were incubated overnight and harvested for 3 H counting. The counts obtained in nonstimulated samples were subtracted from the corresponding counts in stimulated samples for background correction. The resulting values were then related to the background-corrected values obtained in control mice to give the inhibition of proliferation as % of control.
Histological analysis
The thymus and spleen were fixed in 4% formalin, embedded Survival and other statistical analyses treatment groups, however, a slight, but statistically significant difference suggested relatively less toxicity for DBM at both Probit analysis of survival was performed using the SOLO Statistical program package (Version 3.0, BMDP Statistical dose levels. This difference disappeared by day 7 when the spleen weight started to rise. By day 21 the spleens of all drugSoftware Inc, Los Angeles, CA, USA). Differences among multiple groups were tested for significance by ANOVA, followed treated mice reached the normal weight range, and in BUtreated animals even exceeded it. by pairwise comparisons between the groups by Student's ttest. Differences between groups were considered significant To assess possible differential toxicity of drug treatments on T vs B cells in the spleen at the time of major cytoreduction, at P р 0.05 (two-tailed).
ie on day 3, we have measured the absolute mass of T cells in the spleen by multiplying the organ weight (Figure 1 ) with the percentage of Thy-1.2 positive cells in the corresponding Results splenocyte suspension. As shown in Figure 2 , despite the overall diminution of the spleens relative to control, the T cell pool Establishment of equitoxic treatments with DBM and BU remained unaltered following treatment with either drug or dose. This implies that the cytotoxic effects of DBM and BU led to cell death only in the non-T cell fraction of splenocytes, Because of the relative insolubility of DBM and BU and the variety of vehicles and routes of administration chosen by which consists primarily (approximately 95%) of B cells in the mouse. 18 Thus, the difference between DBM and BU in their various investigators (for example dimethyl sulfoxide in arachis oil, Tween 80, or acetone in corn oil or water 14 ) , the spleen weight reducing effects might have arisen solely as a consequence of differential toxicity on B cells. previously reported LD 50 values in mice show substantial variation in the literature for both drugs. [14] [15] [16] [17] We have therefore In attempts to test the latter claim in a B cell function assay, and to clarify whether the apparent lack of T cell toxicity by determined the LD 50 of DBM and BU under our experimental conditions. Mice were randomized in 18 treatment groups DBM and BU in the structure (FACS) analysis also bears out when T cell function is studied, we have analyzed the prolifer-(DBM: 700, 900, 1100, 1200, 1400, 1600, 1800, 2000 and 2700 mg/kg; BU: 5, 10, 20, 40, 50, 80, 90, 100, 110 mg/kg, ative response of splenocytes to LPS and to ConA ex vivo, on day 3 following drug treatments. Table 1 shows that LPSwith eight to 10 animals in each group), and mortality was followed daily for at least 2 weeks. Probit analysis of survival, induced lymphocyte proliferation, taken as an index of B cell function, was significantly reduced in both treatment groups performed as described in the Materials and methods, gave 1500 ± 129 mg/kg and 62 ± 7 mg/kg as the LD 50 for DBM and relative to control, and that the inhibitory effect of BU was significantly more expressed than that of DBM. In addition, BU, respectively. In the studies described below, mice were injected with the above LD 50 doses, or with their half (ie with the inhibitions of 3 H-thymidine uptake by the two drugs were comparable with their non-T cell pool-reductive effects 750/850 mg/kg DBM or 30 mg/kg BU). presented in Figure 2 , which observations together provide further evidence for the differential toxicity of DBM and BU on splenic B cells.
The effects of DBM and BU on the spleen and splenocyte function Table 1 also shows that the ConA-induced proliferative response of splenocytes was significantly reduced by DBM and BU, suggesting that the toxicity of these drugs on mature Figure 1 shows the changes in spleen weight as a function of time following treatment with 1/2 × LD 50 or LD 50 of DBM and T cells, which was not manifested in the membrane marker analysis of resting T cells, became apparent when these cells BU. On day 3 the spleen mass was significantly reduced in all Effect of mitobronitol and busulphan on mouse splenic lymphocyte content. On day 3 following drug treatments the spleen was removed, weighed and analyzed for Thy-1.2 positive cell content (a pan-T cell surface marker) as described in the Materials and methods. Based on the total organ weight and T cell fraction, the T cell pool was calculated (filled bars, mean ± s.d.). The residual spleen mass, referred to as 'non-T cell pool' (empty bars), has been stacked over the T cell pool to illustrate the relative distribution of T and B cells in the whole organ. Note that the error bars on the combined (filled and empty) columns represent the mean and s.e.m. of the weight data, and are the same as shown in Figure 1 . There was no significant difference between the T cell pools in the different groups.
Figure 3
The cytoreductive effect of mitobronitol and busulphan on mouse thymus, and time course of regeneration. The bars represent Table 1 Effect of mitobronitol and busulphan on the in vitro prothe means ± s.e.m. for five to six mice. ‫,ء‬ Significant difference at liferative response of spleen cells to mitogens P Ͻ 0.05. Similar experiments as presented in Figure 1 .
Drug Dose
Proliferative response (% of control) (mg/kg) remained significantly lower than normal in BU-treated mice LPS (10 g/ml)
ConA (5 g/ml)
up to at least 10 weeks (data not shown). Consistent with the above macroscopic changes, micro- later and was less complete on day 21 in BU-treated animals than in those treated with DBM (Table 2 ). injury in BU-treated animals was apparent only on the 7th
All entries are significantly lower than the baseline (100%).
post-treatment week (f). Histologic analysis with lower power a Significant difference (P Ͻ 0.05) relative to DBM. Essentially similar difference between DBM and BU was observed in two additional studies. Table 2 Time-course of thymus regeneration following treatment with mitobronitol and busulphan were stimulated. Unlike in the case of B cells, however, this Drug mg/kg Restitution (weeks) effect was identical with DBM and BU.
Start Subtotal
The effects of DBM and BU on the thymus and that there was no significant difference between the two drugs' cytoreductive effects. Assessment on day 7 showed no, follow-up experiment showed that the thymus weight magnification showed restoration of thymic microarchitecture host, the short-and long-term effects of myeloablation on the immune system are crucial with regard to the occurrence of on day 21 in DBM-treated mice (g), but not in the BU group (h). Improvement in this regard in BU treated mice was visible these complications. Yet, the differences between the immune effects of various conditioning regimens have attracted relaonly on week 7 (i).
Taken together, these observations suggest that the early tively little attention to date in BMT immunology research.
To provide direct comparison of the immune effects of DBM (day 3) cytotoxic effects of DBM and BU in the thymus are essentially identical, while the recovery of thymus following with BU we have used here a simple toxicity model, whereby mice were administered a single i.v. injection of equitoxic cytotoxic drug treatment is significantly enhanced in the case of DBM treatment.
doses of the two drugs, and some structural and functional parameters of the major lymphoid organs were measured over time. Although this model is far from mimicking the complexity of human BMT, it was expected to provide a concepDiscussion tual basis for correlating the beneficial effect of DBM preconditioning with immune effects unique to DBM vis-à-vis BU. It has been known that BMT entails a profound impairment of almost all aspects of immunity, enduring over months or
The results suggested two such unique effects: relatively mild short-term toxicity on B cells and an acceleration of the recovyears even after the return of normal lymphocyte counts. [9] [10] [11] 19 Considering that many post-BMT complications, most ery of the thymus following cytotoxic treatment. Concerning the relatively low cytotoxicity of DBM on B importantly acute GVHD and the opportunistic infections, develop as a consequence of the immune deficiency of the cells, the present observations are in keeping with previous human data obtained in DBM/Ara-C/Cy-preconditioned BMT protection against clinically important immunodeficiencies following intensive chemotherapy. 29 These data together give recipients, which indicated early recovery and supernormal percentage of IgM + B cells for the whole follow-up period. 13 support to the hypothesis that the reduction of post-BMT complications after DBM preconditioning could be due, in A sparing effect of DBM on certain specific immune responses was demonstrated earlier in murine studies, too. 15, 20 Namely, addition to the relatively mild B cell toxicity, to a relative lack of long-term thymus toxicity. The resulting acceleration of the the rat experiments by Elek et al 20 showed a lack of inhibitory effect of chronic, low doses of DBM on anti-albumin antibody return of specific T cell immunity would explain the reduced occurrence of infections and of acute GVHD in DBM-preconproduction following immunization with a mixture of serum antigens, although the stereoisomer of DBM (dibromodulcitol) ditioned patients. The latter, GVHD prophylactic effect of thymus-educated T cells can be conceived as a result of the exerted significant inhibition. In the study of Petrányi et al 15 chronic, subtoxic doses of DBM even potentiated IgM proattenuation of the GVHD-causing alloresponse of donor lymphocytes. It should be noted in this regard that the GVH, duction by B cells in mice, despite powerful inhibition of T cell-mediated skin graft rejection.
engraftment-promoting and/or antileukemic effects of donor T cells are performed by different, functionally separable lymThe pertinence of B cell integrity in reducing the occurrence of post-BMT infections is straightforward, but it can contribute phocyte phenotypes, 30-32 thus a strengthening of host-versusgraft reaction would not necessarily entail the loss of to the reduction of GVHD as well, due to the fact that humoral immunity plays an essential role in protecting against enteral engraftment-promoting and/or antileukemic effects of donor T cells, provided the reaction is sufficiently selective and and epidermal bacterial invasions, both of which can precipitate acute GVHD. 12, 21 Consistent with the latter contention, limited.
As mentioned, DBM and BU are alkylating agents that exert Chan et al 22 have shown high (close to 40%) frequency of acute GVHD in patients in whom the recovery of B cells was cytostatic effects primarily through interfering with nucleic acid functions. Concerning the molecular basis for the differsignificantly delayed during the early post-BMT period.
We have found no changes in the absolute amount of T ences described in the present study, DBM has numerous features that are not shared with BU or most other alkylating cells in the spleens following treatment with DBM or BU, although the proliferative response of suspended splenocytes agents. These include the extended persistence in the blood and cytoplasm, a polarizing effect on DNA and enzymes, the to ConA was significantly and equally inhibited by these drugs. This apparent discrepancy can be rationalized by conrelease of protons and bromide anions subsequent to the alkylation reaction, and an antimetabolite-like effect (through sidering that both drugs are alkylating agents (see below), affecting primarily dividing cells. The cell proliferation assay bromine-containing three-carbon metabolites). 33, 34 The latter fact led to the classification of DBM as an intermediate-type may therefore be more sensitive in showing cytotoxic drug effects than the membrane marker assay, which quantitates myelotropic agent displaying both alkylating and antimetabolite characteristics. 34 Nevertheless, it is not known at resting T cells in which the damage to DNA has not yet manifested. Our finding that both drugs caused massive early cell present which of these special properties account for the differential immune effects in comparison with BU. death in the thymus is not inconsistent with the above assertion, as the thymus of mice is known to contain up to In summary, the presented observations in mice raise the possibility that a relative sparing of B cells and hastening of 90% rapidly cycling CD4 + /CD8 + immature T cells. It remains to be established, however, why B cells, and not rapidly thymus-dependent cellular immune recovery could contribute to the reduction of complications following BMT with DBM cycling thymocytes or stimulated T cells showed reduced sensitivity to DBM in comparison with BU.
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